Wellreme Wart Remover

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. It is recommended to soak the wart in warm water for approximately 5 minutes to facilitate the removal process. After soaking, the area must be dried completely.

Using a cotton swab, a sufficient amount of the medication should be applied to ensure complete coverage of each wart. Following application, the treated area should be allowed to dry.

This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition.

The product should not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes, as these areas may be sensitive or require specialized treatment.

Additionally, individuals with diabetes or poor blood circulation should avoid use, as these conditions may increase the risk of adverse effects.

Warnings and Precautions

For external use only. It is imperative that healthcare professionals advise patients to adhere strictly to this guideline to prevent unintended ingestion or misuse.

In the event of accidental ingestion, immediate medical assistance is required. Patients should be instructed to contact emergency medical services or the Poison Control Center at 1-800-222-1222 without delay.

Healthcare providers should counsel patients to discontinue use and seek medical advice if discomfort persists. Continuous monitoring of the patient's condition is essential to ensure safety and efficacy.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort persists. This recommendation is crucial to ensure the safety and well-being of individuals using the product.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Wellreme Wart Remover (salicylic acid 17% wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The available prescribing information does not provide specific data regarding the use of this product during pregnancy. Consequently, there are no established safety concerns, dosage modifications, or special precautions outlined for pregnant patients. Healthcare professionals should exercise caution when considering the use of this product in women of childbearing potential and weigh the potential risks and benefits. It is advisable to monitor any emerging data related to fetal outcomes as it becomes available.

Lactation

There are no specific warnings or considerations regarding nursing mothers or lactation associated with WELLREME WART REMOVER (salicylic acid 17% wart remover liquid). The available data does not indicate any known effects on breastfed infants or excretion in breast milk. Therefore, lactating mothers may use this product without specific concerns related to breastfeeding.

Renal Impairment

Dosage adjustments may be necessary for patients with reduced renal function. It is important to monitor renal function tests regularly in patients with known kidney problems. Additionally, clinicians should consider creatinine clearance when determining the appropriate dosage for patients with renal impairment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may arise from an overdose. Common symptoms may include, but are not limited to, severe drowsiness, confusion, respiratory distress, or any other unusual clinical manifestations.

Management of an overdose should be tailored to the individual patient and may involve supportive care, including monitoring vital signs and providing symptomatic treatment as necessary. In cases of significant overdose, consultation with a poison control center or a medical toxicologist is recommended to determine the most appropriate course of action.

It is crucial for healthcare professionals to educate patients and caregivers about the importance of adhering to prescribed dosages and to provide guidance on what to do in the event of a suspected overdose.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events have been documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important to instruct patients not to use the product on irritated skin or on any areas that are infected or reddened. Additionally, patients should be cautioned against applying the product on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Special consideration should be given to patients with diabetes or poor blood circulation, as they may be at increased risk.

Patients should be informed to discontinue use and consult a doctor if discomfort persists after application. It is crucial to emphasize the importance of avoiding contact with the eyes; if the product accidentally enters the eye, patients should flush the eye with water for 15 minutes. Providers should remind patients that the product is non-edible.

Finally, healthcare providers should instruct patients to cap the product tightly and store it at room temperature, away from heat sources, to maintain its efficacy and safety.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is protected from excessive heat, specifically temperatures exceeding 37°C (99°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

The medication is administered topically, with the recommended frequency being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Wellreme Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)